Ponsegromab is a monoclonal antibody that works as a GDF-15 inhibitor. It is developed by Pfizer for cancer cachexia.
In September 2024, Pfizer disclosed that ponsegromab led to significant body weight increases in patients with non-small cell lung cancer, pancreatic cancer, or colorectal cancer in a phase 2 clinical trial.
